期刊文献+

硼替佐米为基础的方案治疗华氏巨球蛋白血症5例 被引量:1

Five cases of Waldenstrm's macroglobulinemia treated with bortezomib-based regimens
原文传递
导出
摘要 华氏巨球蛋白血症(Waldenstrm's macroglobulinemia,WM)是B淋巴细胞增殖性疾病,其特点是骨髓中出现浆细胞样淋巴细胞浸润,血清中检测到单克隆IgM。无症状的WM患者可不予以治疗,但应定期随访观察,当患者出现以下症状时应给予治疗:血红蛋白〈100g/L、血小板〈100×10^9/L、明显的腺体肿大或器官肿大、有临床症状的高粘滞血症、严重的神经病变、淀粉样变、冷球蛋白血症、冷凝集素病以及疾病转化的证据。
出处 《临床血液学杂志》 CAS 2016年第5期760-762,共3页 Journal of Clinical Hematology
基金 江苏省科教兴卫工程-临床血液学中心(ZX201102) 江苏省血液病临床研究中心(江苏省科技厅生命健康专项-BL2012005)资助
关键词 华氏巨球蛋白血症 硼替佐米 Waldenstrom's macroglobulinemia bortezomib
  • 相关文献

参考文献8

  • 1Dimopoulos MA,Gertz MA,Kastritis E,et al.Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobuliemia[J].J Clin Oncol,2009,27:120-126.
  • 2Dimopoulos MA,Chen C,Kastritis E,et al.Bortezomib as a treatment option in patients with Waldenstrom's macroglobulinemia[J].Clin Lymphoma Myeloma Leuk,2010,10:110-117.
  • 3Louw VJ,Webb MJ.Prognosis and treatment of Waldenstrom's macroglobulinemia[J].Transfus Apher Sci,2010,42:193-197.
  • 4高文,陈文明,陈世伦.硼替佐米治疗难治性华氏巨球蛋白血症一例并文献复习[J].白血病.淋巴瘤,2009,18(7):430-431. 被引量:1
  • 5肖毅,张义成,张东华,孙汉英,刘文励,周剑峰.硼替佐米联合地塞米松治疗华氏巨球蛋白血症的疗效观察[J].中国癌症杂志,2010,20(12):930-933. 被引量:2
  • 6Dimopoulos MA,Anagnostopoulo A,Kyrtsonis MC,et al.Treatment of relapsed or refractory Waldenstrom's macroglobulinamia with bortezomib[J].Haematologica,2005,90:1655-1658.
  • 7Treon SP,Hunter ZR,Matous J,et al.Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia:results of WMCTG Trial 03-248[J].Clin Cancer Res,2007,13:3320-3325.
  • 8Dimopoulos MA,Kyle RA,Anagnostopoulos A,et al.Diagnosis and management of Waldenstrom's macroglobulinemie[J].J Clin Oncol,2005,23:1564-1577.

二级参考文献12

  • 1刘爱军,陈文明,李利红.多发性骨髓瘤药物治疗的新进展[J].中国癌症杂志,2006,16(12):1083-1087. 被引量:3
  • 2Jagannath S,Richardson PG,Barlogie B,et al.Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bnrtezomib alone[J].Hacmatologica,2006,91(7):929-934.
  • 3Dimopoulos MA,Chen C,Kastritis E,et al.Borteznmib as a treatment option in patients with Waldenstr(o)m macroglobulinemia[J].Clin Lymphoma Myeloma Leuk,2010.10(2):110-117.
  • 4Treon SP.How I treat Waldenstr(o)m macroglobulincmia[J].Blood,2009,114(12):2375-2385.
  • 5Pascal L,Gay J,Willekens C,et al.Bortezomib and Waldenstrom's macroglobulinemia[J].Expert Opin Pharmacother,2009,10(5):909-916.
  • 6Chen C,Kouroukis CT,White D,et al.Bortezomib in relapsed or refractory Waldenst(o)m's maeroglobulinemia[J].Clin Lymphoma Myeloma,2009,9(1):74-76.
  • 7Chen CI,Kouroukis CT,White D,et al.Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia:a phase Ⅱ study of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(12):1570-1575.
  • 8Dimopoulos MA,Anagnostopoulos A,Kyrtsonis MC,et al.Treatment of relapsed or refractory Waldenstr(o)m's macroglobulinemia with bortezomib[J].Haematologica,2005,90(12):1655-1658.
  • 9Treon SP,Hunter ZR,Malous J,et al.Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia:results of WMCTG Trial 03-248[J].Clin Cancer Res,2007,13(11):3320-3325.
  • 10Treon SP,Ioakimidis L.Soumerai JD,et al.Primary therapy of Waldenstr(o)m macroglobulinemia with bortezomib,dexamethasone,and rituximab:WMCTG clinical trial 05-180[J].J Clin Oncol,2009,27(23):3830-3835.

共引文献1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部